Welcome to our dedicated page for Azenta SEC filings (Ticker: AZTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for Azenta, Inc. (Nasdaq: AZTA), a life sciences company focused on cold-chain sample management and multiomics services. These regulatory documents offer detailed insight into how Azenta reports its financial performance, governance practices and executive compensation.
Core filings include the annual report on Form 10-K and quarterly updates on Form 10-Q, where Azenta discusses revenue from its Sample Management Solutions and Multiomics segments, separates products and services revenue, and explains trends in gross margin, operating expenses and adjusted EBITDA. Investors can review these filings to understand the contribution of sample storage, biorepository services and genomic analysis to the overall business.
Azenta’s current report filings on Form 8-K disclose material events such as quarterly and annual financial results, including segment performance and key metrics. For example, the company has furnished press releases detailing revenue growth, margin expansion and cash and liquidity positions, which are incorporated by reference into 8-K filings under Item 2.02.
The definitive proxy statement on Schedule 14A (DEF 14A) describes the structure of the Board of Directors, committee responsibilities, environmental, social and governance topics, and the executive compensation framework. It also outlines proposals submitted to shareholders, such as the election of directors, advisory votes on executive pay, amendments to the equity incentive plan and ratification of the independent auditor.
On Stock Titan, Azenta’s filings are updated as they appear on EDGAR, and AI-powered summaries can help explain lengthy documents like the 10-K, 10-Q, 8-K and DEF 14A. Users can quickly identify segment disclosures, non-GAAP reconciliations, compensation details and other key items without reading every page of the underlying filing.
Azenta, Inc. announced its financial results for the fiscal quarter ended December 31, 2025 through a press release dated February 4, 2026. The company furnished this release as Exhibit 99.1, rather than treating it as formally filed for liability purposes. The disclosure also highlights that the release contains forward-looking statements and directs readers to the cautionary note in the press release for a discussion of related risks and uncertainties.
Azenta, Inc. reported that Alan P. Malus resigned from its Board of Directors, effective January 29, 2026. He also stepped down from his role on the Human Resources and Compensation Committee.
The company stated that his resignation was not due to any disagreement over operations, policies, or practices. Instead, he accepted full-time responsibilities with another company, which will limit the time he can devote to Azenta board duties.
Azenta, Inc. held its Annual Meeting of stockholders on January 28, 2026, where investors approved several key proposals. Stockholders elected all nominated directors to the board, with each nominee receiving a substantial majority of votes cast.
Stockholders approved, on a non-binding advisory basis, the overall compensation of Azenta’s named executive officers. They also approved an amendment to the Company’s 2020 Equity Incentive Plan to increase the number of shares reserved for issuance by 2,750,000, expanding the pool available for future equity awards. In addition, stockholders ratified the appointment of PricewaterhouseCoopers LLP as Azenta’s independent registered public accounting firm for the 2026 fiscal year.
Dimensional Fund Advisors LP filed an amended Schedule 13G reporting beneficial ownership of 2,099,441 Azenta Inc common shares, representing 4.6% of the outstanding class as of the reported date. Dimensional has sole power to vote 2,061,526 shares and sole power to dispose of 2,099,441 shares.
The shares are held across various funds and accounts for which Dimensional or its subsidiaries act as adviser or manager, and all securities are owned by those funds rather than by Dimensional itself. Dimensional states that the holdings are maintained in the ordinary course of business and are not intended to change or influence control of Azenta.
Azenta, Inc. is asking shareholders to vote at a virtual-only annual meeting on January 28, 2026, with a record date of December 3, 2025. Shareholders will elect ten directors, hold an advisory vote on executive pay, approve an increase of 2,750,000 shares reserved under the 2020 Equity Incentive Plan, and ratify PricewaterhouseCoopers LLP as independent auditor for fiscal 2026.
The board is led by an independent chair, and nine of ten director nominees are independent, with an average tenure of 2.7 years and 40% gender, racial or ethnic diversity. Azenta highlights ESG oversight, board refreshment, and strong governance practices, including annual say-on-pay and stock ownership guidelines. The company reports fiscal 2025 revenue growth of 4% (3% organic) and 310 basis points of margin expansion, and is pursuing a sale of its B Medical business, which has been reclassified as discontinued operations.
Azenta, Inc. (AZTA) reported an equity award to its President and CEO, John Marotta. On 11/24/2025 he received a grant of 122,269 restricted stock units (RSUs) of Azenta common stock at a price of $0.00 per unit, recorded as an acquisition of non-derivative securities. Following this grant, he beneficially owns 217,268.78 shares of common stock.
The RSU award was sized by dividing a target award value by the average closing price of Azenta’s common stock over the 20 trading days ending on the grant date. These RSUs are subject to time-based vesting, with 33-1/3% of the units scheduled to vest each year, beginning on November 24, 2026.
Azenta, Inc. (AZTA) executive Lawrence Y. Lin reported an equity award of company stock. On 11/24/2025, the EVP, CFO and Treasurer received a grant of 36,681 restricted stock units (RSUs) of Azenta common stock at a price of $0.00 per unit. Following this grant, he beneficially owns 79,655 shares of Azenta common stock in total, held directly.
The RSUs are subject to time-based vesting and are scheduled to vest in three equal annual installments of 33-1/3% each year, beginning on November 24, 2026. The number of RSUs granted was calculated by dividing a target award value by the average closing price of Azenta’s common stock over the 20 trading days ending on the grant date.
Azenta, Inc. (AZTA) reported an equity compensation grant to one of its senior executives. On November 24, 2025, the company granted 16,303 restricted stock units (RSUs) of its common stock to its SVP and Chief Human Resources Officer, Olga Pirogova, with no cash paid upon grant and a stated price of $0.00 per unit.
The filing states that the number of RSUs was determined by dividing the target award value by the average closing price of Azenta’s common stock over the 20 trading days ending on the grant date. These RSUs are subject to time-based vesting, with 33 1/3% vesting each year beginning on November 24, 2026. Following this grant, the reporting person beneficially owns 33,038 shares of Azenta common stock.
Azenta, Inc. (AZTA) reported an equity award to one of its senior executives. On 11/24/2025, the company’s SVP and GM, Multiomics received 13,042 restricted stock units (RSUs) of Azenta common stock at a grant price of $0.00 per unit. After this grant, the executive beneficially owns 38,755 shares of Azenta common stock in total, held directly.
The filing explains that the RSU amount was calculated by dividing the target award value by the average closing price of Azenta’s common stock over the 20 trading days ending on the grant date. These RSUs are subject to time-based vesting and will vest in three equal installments of 33 1/3% per year, starting on November 24, 2026.
Azenta, Inc. (AZTA) reported an equity award to a senior executive. On November 24, 2025, the company’s SVP, General Counsel & Secretary acquired 34,235 shares of common stock through a grant of restricted stock units (RSUs) at a price of $0.00 per share. Following this grant, the executive beneficially owns 72,014 shares of Azenta common stock in direct ownership.
The RSUs were granted based on a target award value divided by the average closing price of Azenta’s common stock over the 20 trading days ending on the grant date. These RSUs are subject to time-based vesting and will vest in three equal installments of 33-1/3% per year, beginning on November 24, 2026.